CD22 and acute lymphoblastic leukemia: Schultz et al. conducted a Phase I trial consisting of 19 pediatric and adult patients with R/R B-ALL utilizing a bivalent CAR construct with dual targeting of CD19/CD22 (NCT03233854 and NCT03241940).